Hologic Inc. (HOLX) recently launched the next-generation NovaSure 6mm global endometrial ablation (GEA) system in an effort to expand in the growing GYN Surgical market. This next-generation NovaSure system includes a smaller diameter ablation device along with an advanced interactive touchscreen radiofrequency controller. Hologic expects full market release of the same in Dec 2014 globally.
Hologic’s NovaSure is a minimally invasive endometrial ablation system designed to treat abnormal uterine bleeding (AUB). According to Hologic, unlike other endometrial ablation treatment techniques, this procedure can be personalized as per patient requirement with a scientific endpoint. Moreover, there is no possibility of side-effects and treatment delays as no hormonal pre-treatment is needed. For the past 10 years, the NovaSure ablation profile has proven itself superior to other endometrial ablation modalities.
Hologic’s management is encouraged by the positive growth achieved at the company’s GYN surgical segment over the last two consecutive quarters. This marked a recovery from the negative outcome that had been persisting over several quarters prior to that. The improvement was primarily driven by strong double-digit growth in Hologic’s global MyoSure franchise as well as single-digit growth of NovaSure in the international market.
Notably, although the company experienced a decline in its domestic NovaSure sales, a gradual slowdown was observed in the decrement. Globally, Hologic’s MyoSure system gained strong market adoption with rise in unit sales worldwide.
To date, Hologic has performed more than 2 million NovaSure endometrial ablation treatment procedures. This marks an important milestone for Hologic’s GYN Surgical segment that is expected to reinforce confidence among investors looking forward to invest in this particular company.
Currently, Hologic has a Zacks Rank #3 (Hold). Some well-ranked stocks in the medical instruments industry are Edwards Lifesciences Corp. (EW), IDEXX Laboratories, Inc. (IDXX) and Inogen, Inc. (INGN). All the three stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment